Investment bank Piper Sandler has reaffirmed its overweight ratings on BioMarin Pharmaceutical and CVS Health, highlighting robust pipeline developments and stable revenue projections. The firm also noted that ongoing policy discussions around the 340B drug discount program present manageable risks for CVS.

The transcript for CVS Health's second-quarter 2026 earnings call has been made public, offering insights into the company's financial results and future projections.

CVS Health is expanding its GLP-1 (glucagon-like peptide-1) offerings through a new partnership with Lilly. This collaboration aims to enhance access to and management of medications for conditions like diabetes and weight loss.

An article provides an analysis of the safety and sustainability of CVS Health’s dividend.

Jim Cramer discusses why CVS Health Corporation (CVS) is currently in a strong market position.

CVS Health's stock performance is reportedly reflecting its three-dollar earnings prize, indicating investor reaction to its financial results.

CVS Health (CVS) is facing increased scrutiny following the release of a recent healthcare report, prompting closer examination of its operations and market position.

CVS Health is being highlighted as one of the ten dividend stock picks favored by billionaire investor Larry Robbins.

CVS Health made an announcement that was perceived as highly positive for investors in Eli Lilly stock, leading to a favorable market reaction.

CVS Health has reinstated coverage for Eli Lilly's weight-loss drug Zepbound.

Financial analyst Jim Cramer expressed his strong positive opinion on CVS Health, explaining his reasons for considering it the best in its sector.

An analyst report offering insights and evaluations for CVS Health Corp has been released.

CVS Health stock has hit a new 52-week high following the release of strong first-quarter results, with analysts suggesting further potential for growth.

CVS Health's ongoing transformation efforts are reportedly encountering a challenging valuation floor in the market.

Financial analysts are debating the investment prospects of value stocks, with one article specifically evaluating CVS Health's potential as a buy. Another piece questions whether a struggling value stock could face a complete loss of value.

An expert analysis indicates that CVS Health Corporation (CVS) has a strong investment case, supported by recent legal clarity and the company's fundamental core strengths.

CVS Health has begun rolling out smaller 'pharmacy-only' stores as part of its reaffirmed plans to open 60 new locations and expand its retail operations this year.

CVS Health has warned it may close all 134 of its locations in Tennessee if a new legislative bill is enacted, with a spokesperson calling the proposal 'bad for Tennessee'.

An analyst report has been published for CVS Health Corp, detailing financial analysis and projections for the company.

CVS Health stock has been beating the market in 2026, with Wall Street analysts projecting an additional 22% increase. This positive outlook reflects investor confidence in the company's performance and future prospects.

CVS Health's stock experienced a decline even after the company announced a raised financial outlook.

CVS Health has revised its 2026 financial outlook upwards after reporting stronger-than-expected results for its second quarter.

CVS Health announced a nearly threefold increase in its second-quarter net income, reaching $2.9 billion, attributed to the company's improved management of Aetna health plan costs.

CVS Health Corporation's stock increased, attributed to better operational execution and a positive outlook for payer margins.

This article highlights notable healthcare headlines for the week, focusing on companies like UnitedHealth, Vertex, and CVS Health.

An analysis compares the revenue trends of two major healthcare companies, CVS Health and UnitedHealth.

CVS Health stock significantly outperformed the broader market today, with analysts pointing to specific factors contributing to its strong performance.

CVS Health executives are discussing how the company is leveraging artificial intelligence and other technologies to streamline administrative tasks and provide more proactive patient care experiences.

An analysis investigates whether CVS Health stock is currently outperforming the S&P 500 index.

Mizuho increased its price target for CVS Health by $8, while DA Davidson lowered its price target for Roblox stock. These adjustments reflect updated analyst expectations for the respective companies.

Financial analysts are recommending specific "cheap stocks," including Enterprise Products Partners (EPD) and CVS Health (CVS), as potential long-term investments for the next decade.

CVS Health (CVS) has seen its price target increased by $1, reflecting analyst adjustments to its valuation.

CVS Health stock has broken out, with technical indicators turning bright green, suggesting positive momentum.

CVS Health announced strong financial results for the first quarter, surpassing analyst expectations and subsequently increasing its full-year guidance.

Analysts on Wall Street are presenting mixed views regarding the future performance of CVS Health stock, with some bullish and others bearish on its prospects.

Jefferies analysts have advised investors to buy "income darlings" like Target and CVS Health to stabilize portfolios amidst current geopolitical volatility.

CVS Health has reportedly received a $13 billion reprieve, leading to expectations of continued stock growth. The article discusses the reasons behind this positive financial outlook for the company.

An analysis reviews the performance of CVS Health stock over the past five years, indicating that a $100 investment would not have resulted in a loss.

Bernstein has upgraded CVS Health (CVS) stock to Outperform from Market Perform, suggesting a more positive investment outlook for the company.

CVS Health is set to launch an AI-enabled platform in collaboration with Google Cloud, aiming to enhance its healthcare services and operational efficiency through advanced artificial intelligence.

Articles provide analysis on the stock performance of various companies like CVS Health, Trane Technologies, and McKesson Corporation, comparing them to broader market indexes, alongside general market talk and sentiment.

CVS Health has appointed an executive from JPMorgan Chase to its board of directors. This addition is expected to bring new expertise and perspectives to the company's governance.

Multiple companies, including The New York Times Company, CVS Health, and Payoneer Global, are releasing or previewing their second-quarter 2026 earnings results.

CVS Health saw gains in its Q2 earnings, surpassing expectations primarily due to strong performance from its insurance unit.

An analysis explores the sentiment of Wall Street analysts regarding CVS Health stock, providing insights into their recommendations and outlook for the company.

An analysis delves into the factors and considerations for patient holders investing in CVS Health stock, examining its current valuation and future prospects.

Major health insurance companies, including UnitedHealth Group, CVS Health, and Cigna, are taking legal action against states that have enacted new laws targeting their pharmacy businesses.

The Florida Attorney General's office has launched an investigation into CVS Health regarding alleged anticompetitive practices.

A leading Wall Street analyst suggests that CVS Health stock could see a 13% increase, leading to questions about whether investors should buy more shares.

An analysis highlights several companies, including Williams Companies, CVS Health, and Netflix, as leading blue-chip stock options currently trading under $100. These companies are presented as strong investment opportunities within that price range.

Glenview Capital has confirmed that CVS Health (CVS) remains one of its principal investment holdings, indicating continued confidence in the healthcare company.

CVS Health stock is currently experiencing a significant surge, prompting speculation on whether this rally is just beginning and if the positive momentum will continue.

CVS Health is continuing its portfolio revamp with the sale of its Omnicare long-term care pharmacy business, streamlining its operations and focusing on core services.

CVS Health Corporation (CVS) has announced updates to its commercial formularies, which could impact prescription drug coverage for its members.

This week's notable healthcare headlines highlight developments concerning major industry players such as UnitedHealth, Pfizer, and CVS Health.

CVS Health has increased its financial guidance for 2026. This decision follows a strong first-quarter earnings beat and improved controls over medical costs.

CVS Health's stock, despite its slow movement, is identified as potentially offering a surprise for bullish options traders.

An article provides analysis and considerations for investors regarding CVS Health stock, specifically in anticipation of developments before May 6.

CVS Health has reiterated its plans to expand its store footprint by opening 60 new locations throughout the current year, with the Wall Street Journal confirming the company's continued growth in its retail operations.

CVS Health's stock has seen a rise following a six-session losing streak.

CVS Health and Google have partnered to launch a new AI business focused on personalizing healthcare services for consumers.

CVS Health is seeing heavy and directionally bearish put option volume in the market.

Financial analyst Jim Cramer provides his opinions and detailed discussions on the stock performance and outlook for several major companies, including Disney, General Motors, CVS Health, Salesforce, and Corning.